CAELUS PHARMACEUTICALS B.V.;ACADEMISCH MEDISCH CENTRUM
发明人:
NIEUWDORP, MAX,DE VOS, WILLEM MEINDERT
申请号：
CA2851602
公开号：
CA2851602A1
申请日:
2012.08.30
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
The present invention describes use of Eubacterium hallii etrel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria, as a medicament, in particular for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitusas well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes)in a subject in need thereof, said method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
